Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
αDC1 Vaccine + CKM in Peritoneal Surface Malignancies
NCT02151448Phase 2Completed
- Start
- Jul 2014
- Primary completion
- Feb 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of alpha-type-1-polarized dendritic cell vaccine in Peritoneal surface malignancies (PSM). Started Jul 2014; status: completed.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
Peritoneal surface malignancies (PSM)
Beyond the preview
Go deeper on NCT02151448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151448.